Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of highly effective tyrosine kinase inhibitors (TKIs) and bispecific antibodies. These therapies have considerably improved outcomes for patients and many achieve durable remissions, raising the debate of whether allogeneic hematopoietic stem cell transplantation (alloHSCT) should still be offered to all patients with ALL.
In this podcast featuring Mohamad Mohty, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, and Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discuss the relevance of alloHSCT in the current therapeutic landscape for ALL.
The post COSTEM: the role of alloHSCT in ALL appeared first on VJHemOnc.
